Skip to content
Lower risk Drug recall · FDA · Published October 28, 2020

Teva Mesalamine Tablets Recall: Failed Dissolution Testing

Teva Pharmaceuticals USA recalls specific lots of Mesalamine Delayed-Release Tablets due to failed dissolution testing. Consumers should contact the company for details.

🇺🇸 FDA recall #D-0069-2021DrugTeva Pharmaceuticals USA ›
Take action

Contact the company

Recalling firmTeva Pharmaceuticals USA400 Interpace Pkwy · Parsippany, NJ 07054-1120
✎ GovInfoNow plain-language explainer

Teva Pharmaceuticals USA is recalling certain lots of Mesalamine Delayed-Release Tablets because they failed dissolution testing. This could mean the medication doesn't work properly as intended. Read more at govinfonow.com/recall/36694-teva-mesalamine-tablets-recall-failed-dissolution-testing.

Source Summary by GovInfoNow · govinfonow.com/recall/36694-teva-mesalamine-tablets-recall-failed-dissolution-testing · Updated October 4, 2026 · FDA enforcement record: FDA #D-0069-2021

Cite this page

“Teva Mesalamine Tablets Recall: Failed Dissolution Testing.” GovInfoNow, updated October 4, 2026. https://govinfonow.com/recall/36694-teva-mesalamine-tablets-recall-failed-dissolution-testing. Based on FDA recall #D-0069-2021 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0069-2021%22&limit=1).

The FDA announced on 2020-10-28 that Teva Pharmaceuticals USA is recalling Mesalamine Delayed-Release Tablets due to failed dissolution specifications. The agency stated the recall was voluntary and initiated by the firm.

How to tell if you have it

  • Brand: Teva Pharmaceuticals USA
  • Product: Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle
  • NDC: 0591-2245-22
  • Lots: 1342498A (Exp. 12/2020), 1342499A (Exp. 01/2021), 1354638A (Exp. 03/2021), 1354639A, 1358274A, 1358448A, 1364618A, 1369884A (Exp. 05/2021), 1366195A, 1369885A, 1373570A (Exp. 06/2021), 1373571A (Exp. 07/2021), 1388571A (Exp. 01/2022), 1395725A, 1396585A, 1397550A, 1399389A (Exp. 04/2022), 1403885A, 1403886A (Exp. 06/2022)
  • Quantity: 133,829 bottles
  • Distribution: Nationwide in the U.S. and PR

The hazard

According to the FDA, out-of-specification dissolution results were obtained during stability testing for the recalled Mesalamine tablets.

Context

GovInfoNow's records show Teva Pharmaceuticals USA has 97 other recalls on record since 2013-10-11. Recent brand recalls include a 2022-01-18 recall of Doxylamine Succinate Tablets for failed dissolution risk, a 2022-01-10 recall of Tretinoin Capsules for failed dissolution testing, and a 2022-01-07 recall of Mimvey Tablets due to mislabeling. Other recent recalls of similar products include Teva Metoprolol Succinate Tablets Recall (2026-01-29), Teva Metoprolol Succinate Extended-Release Tablets Recall (2026-01-29), and Teva Recalls Metoprolol Succinate 50 mg Due to Dissolution Failure (2026-01-29).

How to tell if you have this one

Check the product label for the lot numbers listed: 1342498A through 1403886A. The tablets are prescription-only and come in 120-count bottles.

  • Brand
    Teva Pharmaceuticals USA
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Label

    Look for the lot numbers listed in the recall: 1342498A through 1403886A.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide in the U.S. and PR” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 10 months after the firm started it.

1. Firm started the recall: Oct 28, 202012. FDA classified it Class II: Nov 6, 202023. Published in FDA’s Enforcement Report: Nov 18, 202034. FDA terminated the recall: Aug 26, 2021420202021
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0069-2021 (October 28, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0069-2021 to see it in context.
  • Plain-language summary written by qwen3:4b on October 4, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA